Suchergebnisse - "Griffin, Celina"

PubPharm (5)

1

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer : A Phase 1/2 Open-label Nonrandomized Clinical Trial

enthalten in: JAMA oncology | 2021

von Zhou, C. | Ramalingam, S. | Kim, T. | +15

ErratumIn: JAMA Oncol. 2022 Feb 24;:. - PMID 35201294

2

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers

enthalten in: Clinical pharmacology in drug development | 2021

von Zhang, S. | Jin, S. | Griffin, C. | +4

3

Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers : Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products

enthalten in: Clinical pharmacology in drug development | 2021

von Zhang, S. | Jin, S. | Griffin, C. | +6

4

Characterizing the Sources of Pharmacokinetic Variability for TAK-117 (Serabelisib), an Investigational Phosphoinositide 3-Kinase Alpha Inhibitor : A Clinical Biopharmaceutics Study to Inform Development Strategy

enthalten in: Clinical pharmacology in drug development | 2019

von Patel, C. | Rangachari, L. | Patti, M. | +3

5

Characterizing the Sources of Pharmacokinetic Variability for TAK‐117 (Serabelisib), an Investigational Phosphoinositide 3‐Kinase Alpha Inhibitor : A Clinical Biopharmaceutics Study to Inform Development Strategy

enthalten in: Clinical Pharmacology in Drug Development | 2019

von Patel, C. | Rangachari, L. | Patti, M. | +3

1
[1]